Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Latest Filings

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Oct 30, 2020 1:39pm

187 Views

Post# 31813894

Latest Filings

All the financials and MD&A current are all filed on Sedar .... guessing they need to give a formal NR re filings..update moving forward ... as well I saw that they were in talks with talent holders to extend debt notice to Nov 15/2020 ...so I was thinking today or early part next week to have halt lifted .... and again if they plan on shareholder meeting to jump into phase 1...we are already at Nov ....

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing